All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Looking to reach an audience of 1700+ biotech and pharma professionals? Let’s chat. 👍

THE GOOD
Business Development

Relmada Therapeutics acquires sepranolone (GABA-A modulating steroid antagonist) from Asarina Pharma develop treatment for Tourette syndrome and other compulsive disorders
Small molecule, Tourette syndrome, compulsive disorder - Read more

THE GOOD
Clinical Trials

Equillium and Biocon's itolizumab (targeting CD6) delivers positive Ph2 data in moderate to severe ulcerative colitis versus placebo and adalimumab (targeting CD6)
Monoclonal antibody, ulcerative colitis - Read more

Tonix Pharmaceuticals' touts positive Ph1 data for TNX-1500 (anti-CD40L) in kidney transplant rejection and other autoimmune diseases
Monoclonal antibody, autoimmune, kidney transplant rejection - Read more

Coya Therapeutics' low-dose IL-2 delivers encouraging blood biomarker data in Alzheimer’s disease Ph2 trial
IL-2, interleukin, Alzheimer’s disease - Read more

Denali Therapeutics tividenofusp alfa (IDS modulator) meets safety and biomarker reduction goals in Ph1/2 trial for Hunter syndrome
Fusion protein, Hunter syndrome - Read more

PRESENTED BY CURIE.BIO
Curie.Bio: a better VC model for all biotech founders

Curie.Bio has raised $1.25B in capital and built an 80-person team of proven drug hunters to help founders create impactful medicines. 

We’ve funded >25 companies, supporting programs across every major therapeutic area and drug modality - and our capital-efficient model ensures founders minimize dilution while maximizing success.

We are looking to partner with amazing scientists who are anywhere along the path from an idea to a clinic-ready molecule. 

Have a therapeutic idea worth funding? Pitch us at [email protected] 

⬇️ More Good News ⬇️

THE GOOD
Earnings & Finances

Eli Lilly reports doubled Q4 profits, driven by diabetes and obesity drug sales, with shares rising 5%
Big pharma earnings, diabetes, obesity - Read more

Bristol Myers Squibb Cobenfy launch going smoothly, achieving $10M in Q4 sales with 1,000 weekly prescriptions after historic FDA approval
Small molecule, schizophrenia, big pharma earnings - Read more

AstraZeneca shares rise after announcing potential, and manageable, $4.5M fine to resolve Chinese probe into actions of former employees
Monoclonal antibody, carcinoma, cancer, illegal importation, tax investigation - Read more

THE GOOD
Fundraises

Miist Therapeutics $7M Seed, develops fast-acting inhaled medicines for smoking addiction and migraine
Smoking cessation, migraine, inhaled therapy, drug delivery - Read more

Belite Bio $15M direct offering, developing therapies for retinal degenerative eye diseases
Small molecule, stargardt disease, geographic atrophy, dry age-related macular degeneration - Read more

THE GOOD
Partnerships

Mallia Therapeutics, Northway Biotech partner to manufacture CD83 protein-based hair loss treatment using Pichia pastoris system
Recombinant protein, hair loss, alopecia, manufacturing partnership, CDMO - Read more

Immuneering, Regeneron partner to test IMM-1-104 (dual-MEK inhibitor) and Libtayo (targeting Pd-1) combination therapy for RAS-mutant lung cancer patients
Monoclonal antibody, small molecule, lung cancer, clinical supply partnership - Read more

KYAN Technologies, OncoCare Malaysia partner to expand Optim.AI cancer drug prediction test for difficult-to-treat cancers
Predictive medicine, cancer, AI, precision medicine - Read more

Dr. Reddy’s Laboratories, Henlius Biotech partner to develop and market HLX15 (targeting CD38; Darzalex & Darzalex Faspro biosimilar, Genmab & Janssen)
Monoclonal antibody, multiple myeloma, cancer, biosimilar - Read more

Qureight, Avalyn Pharma partner to evaluate inhaled pirfenidone using AI imaging tech in pulmonary fibrosis trials
Small molecule, pulmonary fibrosis, inhaled therapy, drug delivery, AI, medical imaging, drug development - Read more

Hitachi, ValGenesis partner to deliver digital validation solutions for Japanese life sciences companies
Digital validation, validation lifecycle management - Read more

Essential Pharma and Clinigen expand partnership to distribute four specialty medicines in Japan and Korea through new market agreements
Small molecule, chronic glaucoma, schizophrenia, dementia, Alzheimer’s disease, distribution partnership - Read more

THE GOOD
Product Launches

LinusBio launches hair-based diagnostic test to assess autism risk in young children by analyzing environmental exposures over time
Diagnostic test, autism spectrum disorder, environmental exposure, disease risk factors - Read more

The Chan Zuckerberg Initiative launches Billion Cells Project to create massive cell dataset for AI-powered drug discovery, partnering with genomics companies
Cell data, drug discovery, AI, genomics - Read more

THE GOOD
Research

Existing medicine adalimumab successfully treats Castleman's disease patient, repurposing predicted by AI tool
Monoclonal antibody, Castleman’s disease, drug repurposing, AI - Read more

S6K2 gene inhibition may be a viable path to fighting treatment-resistant melanoma
Melanoma, cancer - Read more

THE BAD
Clinical Trials

AstraZeneca discontinues two Alexion-acquired rare disease drug programs due to poor efficacy results
Small molecule, impaired hepatic function, lupus nephritis, immunoglobulin A nephropathy, enzyme replacement, bone metabolism diseases - Read more

THE BAD
Company Shutdown

Viracta Therapeutics shuts down operations
Small molecule, lymphoma, cancer - Read more

THE BAD
Lawsuits

Hospital group opposes Eli Lilly's 340B rebate model, seeks to join lawsuit against federal government over pricing concerns.
340B Drug pricing program - Read more

GSK’s Zantac woes ain’t over, as a fresh investor lawsuit emerges with allegations of concealment of cancer risk report
Small molecule, cancer risk, heartburn, class-action - Read more

THE BAD
Layoffs

Bristol Myers Squibb announces new $2 billion cost-cutting plan through 2027, including additional layoffs following earlier $1.5 billion reduction
Big pharma, cost-cutting - Read more

AffyImmune Therapeutics conducted layoffs and restructuring in recent weeks, affecting an unspecified number of employees
Cell therapy, thyroid cancer, lung cancer, CAR-T - Read more [Paywall]

X4 Pharmaceuticals cuts 43 jobs, closes Vienna facility, and halts research despite recent FDA approval of WHIM syndrome drug
Small molecule, WHIM syndrome - Read more

THE BAD
Mergers & Acquisition

Alumis investors aren’t jazzed about proposed merger with struggling biotech ACELYRIN
Monoclonal antibody, thyroid eye disease, small molecule, plaque psoriasis - Read more

Bausch + Lomb ends exploration of private sale while still maintaining goal of full separation from Bausch Health Companies Inc
Medical supplies, prescription pharmaceuticals, consumer health, OTC - Read more

THE BAD
Politics & Policy

Hospital group urges Trump to exempt medical supplies from tariffs to protect healthcare access and patient safety
Healthcare access, drug pricing, tariffs - Read more

THE BAD
Strategic Plans

Becton Dickinson splits company, keeping medical device and pharmaceutical systems businesses while divesting diagnostic and bioscience divisions
Divestiture, medical device, diagnostics, drug delivery - Read more

THE UGLY
Politics & Policy

Trump administration reportedly plans major staff reductions at FDA, CDC and other federal health agencies under HHS
Federal health agency, layoffs - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Last thing - if you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here